header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-PUB-100223-25
Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFR{beta}/B-RAF
Murphy, E.A., Shields, D.J., Stoletov, K., Dneprovskaia, E., McElroy, M., Greenberg, J.I., Lindquist, J., Acevedo, L.M., Anand, S., Majeti, B.K., Tsigelny, I., Saldanha, A., Walsh, B., Hoffman, R.M., Bouvet, M., Klemke, R.L., Vogt, P.K., Arnold, L., Wrasidlo, W., and Cheresh, D.A.
Date: 2010
Source: Proceedings of the National Academy of Sciences of the United States of America   107(9): 4299-4304 (Journal)
Registered Authors: Klemke, Richard
Keywords: type II inhibitor, kinase inhibition, pancreatic carcinoma, pericyte, cell-based screening
MeSH Terms:
  • Administration, Oral
  • Angiogenesis Inhibitors/pharmacology*
  • Angiogenesis Inhibitors/therapeutic use
  • Animals
  • Carcinoma, Renal Cell/drug therapy
  • Carcinoma, Renal Cell/metabolism
  • Carcinoma, Renal Cell/pathology*
  • Cell Division/drug effects*
  • Kidney Neoplasms/drug therapy
  • Kidney Neoplasms/metabolism
  • Kidney Neoplasms/pathology*
  • Neovascularization, Pathologic*
  • Pancreatic Neoplasms/drug therapy
  • Pancreatic Neoplasms/metabolism
  • Pancreatic Neoplasms/pathology*
  • Protein Kinase Inhibitors/pharmacology*
  • Protein Kinase Inhibitors/therapeutic use
  • Proto-Oncogene Proteins B-raf/metabolism*
  • Receptor, Platelet-Derived Growth Factor beta/antagonists & inhibitors
  • Receptor, Platelet-Derived Growth Factor beta/metabolism*
  • Zebrafish
PubMed: 20154271 Full text @ Proc. Natl. Acad. Sci. USA
FIGURES
ABSTRACT
Kinases are known to regulate fundamental processes in cancer including tumor proliferation, metastasis, neovascularization, and chemoresistance. Accordingly, kinase inhibitors have been a major focus of drug development, and several kinase inhibitors are now approved for various cancer indications. Typically, kinase inhibitors are selected via high-throughput screening using catalytic kinase domains at low ATP concentration, and this process often yields ATP mimetics that lack specificity and/or function poorly in cells where ATP levels are high. Molecules targeting the allosteric site in the inactive kinase conformation (type II inhibitors) provide an alternative for developing selective inhibitors that are physiologically active. By applying a rational design approach using a constrained amino-triazole scaffold predicted to stabilize kinases in the inactive state, we generated a series of selective type II inhibitors of PDGFRbeta and B-RAF, important targets for pericyte recruitment and endothelial cell survival, respectively. These molecules were designed in silico and screened for antivascular activity in both cell-based models and a Tg(fli1-EGFP) zebrafish embryogenesis model. Dual inhibition of PDGFRbeta and B-RAF cellular signaling demonstrated synergistic antiangiogenic activity in both zebrafish and murine models of angiogenesis, and a combination of previously characterized PDGFRbeta and RAF inhibitors validated the synergy. Our lead compound was selected as an orally active molecule with favorable pharmacokinetic properties which demonstrated target inhibition in vivo leading to suppression of murine orthotopic tumors in both the kidney and pancreas.
ADDITIONAL INFORMATION